Roche’s subsidiary Genentech has successfully expanded the label of Alecensa to include the adjuvant treatment of anaplastic lymphoma kinase-positive, early-stage non-small cell lung cancer following resection.
Tag Archive for: lung cancer
Following disappointing Phase III results in less aggressive non-small cell lung cancer, AstraZeneca on Friday announced that Imfinzi improved progression-free and overall survival in patients with limited-stage small cell lung cancer.
Novocure said on Wednesday that its device met the main goal of a late-stage trial by slowing the progression of cancer to the brain in patients with a type of lung cancer, sending its shares up about 33% in before-the-bell trading.
The drug would be used to treat adults with a type of advanced lung cancer, AstraZeneca said, adding that the FDA’s approval was based on trials which extended median progression-free survival (PFS) by nearly nine months.
The company announced today that the trial failed to show that it significantly improved survival for previously treated patients with advanced non-small cell lung cancer.
The U.S. drugmaker has been doubling down on building future revenue streams as its blockbuster immunotherapy, Keytruda, inches closer to losing key patents, opening the doors for competition from biosimilars.
The U.S. Food and Drug Administration has placed a clinical hold on Iovance Biotherapeutics’ lung cancer therapy trial after a patient death, the company said on Wednesday.
The company announced that it signed an exclusive license and collaboration agreement with SystImmune to develop the biotech’s investigational bi-specific antibody-drug conjugate BL-B01D1 as a treatment for solid tumors.
The experimental personalized mRNA cancer treatment is used in combination with blockbuster drug Keytruda for patients with a type of lung cancer.
The company announced that its experimental therapy in combination with Keytruda to treat a type of lung cancer in previously treated patients did not meet the main goal in a mid-stage study.
